Global Clinical Disorder Treatment Market Highlights 2022 – 2030
The global clinical disorder treatment market is estimated to garner a sizeable revenue and grow at a CAGR of ~6% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence of psychiatric and psychological disorders, and rising cases of substance abuse among adolescents around the world. According to a statistical report titled Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), as of 2017, 264 million people were affected by depression, whereas, dementia affected nearly 50 million people globally. Along with these, mounting need for effective management of anxiety and depression related disorders is also expected to drive market growth in the coming years. Furthermore, many hospitals, clinics and health institutions are organizing campaigns to create awareness about relevant treatment options for clinical disorders among general public. This in turn is projected to offer abundant growth opportunities to the market in the near future.
Get more information on this report: Download Sample PDF
The market is segmented by drug class into antidepressants, anticonvulsants, anxiolytics, atypical antipsychotics, and noradrenergic agents, out of which, the antidepressants segment is anticipated to hold the largest share in the global clinical disorder treatment market. This can be accounted to the high efficacy rate of antidepressants in lowering an individual’s depressive state of mind as compared to other available medications. Apart from these, increasing number of pipeline candidates and product approvals of antidepressants is also predicted to boost the market segment growth in the future. Additionally, on the basis of drug distribution channel, the hospital pharmacy segment is assessed to acquire the largest share during the forecast period owing to the increasing patient visits in hospitals, and high preference of patients to get treatment from hospitals.
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Clinical Disorder Treatment Market Regional Synopsis
On the basis of geographical analysis, the global clinical disorder treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing incidences of substance abuse among teenagers and adults, especially in India and China, and increasing prevalence of clinical disorders in the region. In 2019, approximately 30 million people in South Asia admitted to using cannabis. Along with this, 22 million people consumed opioids in the region that year. Moreover, the market in North America is projected to acquire the largest share during the forecast period ascribing to the rising awareness levels about the symptoms of clinical disorders, and high healthcare spending in the region. In addition, strong presence of prominent market players is also expected to propel the market growth in the region in the coming years.
Get more information on this report: Download Sample PDF
The global clinical disorder treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
Market Segmentation
Our in-depth analysis of the global clinical disorder treatment market includes the following segments:
By Drug Class
- Antidepressants
- Anticonvulsants
- Anxiolytics
- Atypical Antipsychotics
- Noradrenergic Agents
By Indication
- Anxiety
- Depression
By Drug Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Growth Drivers
- Increasing Prevalence of Psychiatric and Psychological Disorders
- Rising Cases of Substance Abuse Among Adolescents Worldwide
Challenges
- Adverse Effects of High Dosage of Treatment Drugs
Top Featured Companies Dominating the Market
- Universal Health Services, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CareTech Holdings PLC
- Behavioral Health Network, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- AstraZeneca Plc
- Bristol Myers Squibb Company
- Johnson & Johnson Services, Inc.
- VistaGen Therapeutics, Inc.
